Immix Biopharma, Inc. (IMMX) Stock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company based in Los Angeles, California, specializes in the development of tissue-specific therapeutics targeting oncollogy and inflammation. Established in 2012, Immix Biopharma is actively advancing a robust pipeline of innovative treatments. Among its key candidates is IMX-110, currently undergoing Phase 1b/2a clinical trials as a potential therapy for soft tissue sarcoma and various solid tumors. The company also focuses on IMX-111, a tissue-specific biologic designed for the treatment of colorectal cancers, and IMX-120, another tissue-specific biologic aimed at addressing ulcerative colitis and severe Crohn's disease.

Immix Biopharma has strategically partnered with BeiGene Ltd. through a clinical collaboration and supply agreement. This collaboration aims to evaluate the combination of IMX-110 with anti-PD-1 therapy Tislelizumab in a Phase 1b clinical trial targeting solid tumors. The company's commitment to advancing therapeutic innovation underscores its mission to address critical unmet medical needs and improve patient outcomes in oncology and inflammatory diseases.

Headquartered in Los Angeles and with operations spanning the United States and Australia, Immix Biopharma leverages its scientific expertise and strategic collaborations to accelerate the development of novel treatments. By focusing on tissue-specific approaches, the company aims to deliver targeted therapies that offer potential advantages over traditional treatments, paving the way for advancements in personalized medicine.